STOCK TITAN

SOPHiA Genetics SA - SOPH STOCK NEWS

Welcome to our dedicated news page for SOPHiA Genetics SA (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on SOPHiA Genetics SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SOPHiA Genetics SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SOPHiA Genetics SA's position in the market.

Rhea-AI Summary
SOPHiA GENETICS, a data-driven medicine leader, will announce its Q1 2024 financial results on May 7, 2024. A conference call discussing the results and business outlook will follow, webcast live on their Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS partners with Syndicate Bio to bring MSK-ACCESS® powered with SOPHiA DDM™ to Africa, revolutionizing cancer diagnostics. Syndicate Bio becomes the first lab in Africa to offer comprehensive genomic profiling and liquid biopsy, addressing the underserved healthcare needs in the region. The collaboration aims to advance precision medicine, accelerate drug discovery, and improve cancer treatment outcomes across the continent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
Rhea-AI Summary
SOPHiA GENETICS announces Unilabs is using its AI technology to detect Homologous Recombination Deficiency (HRD). Unilabs deploys the SOPHiA DDM™ Platform in Switzerland for cancer diagnostics. HRD is a significant predictor of tumor response to treatment, and SOPHiA GENETICS' AI technology provides fast and accurate results for HRD testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
AI
Rhea-AI Summary
SOPHiA GENETICS (SOPH) partners with Strand Life Sciences to advance precision medicine globally. The collaboration aims to provide innovative solutions leveraging genomics technologies and bioinformatics services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
partnership
-
Rhea-AI Summary
SOPHiA GENETICS partners with Laboratorio Barnafi-Krause in Chile to enhance research capabilities for blood disorders, particularly Chronic Lymphocytic Leukemia (CLL), using advanced AI-powered technology. This collaboration aims to revolutionize diagnostic approaches and treatment strategies for leukemia patients in Chile and Latin America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none
-
Rhea-AI Summary
SOPHiA GENETICS partners with University of Saskatchewan to advance research on ovarian cancer care using SOPHiA DDM™ Platform, potentially revolutionizing treatment decisions for ovarian cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
none
Rhea-AI Summary
SOPHiA GENETICS and UroCCR collaborate on a study using a multimodal algorithm to predict post-operative outcomes for renal cell carcinoma patients. The AI model outperformed usual prognostic scores, showing the potential of AI in cancer research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
none
-
Rhea-AI Summary
SOPHiA GENETICS (SOPH) CFO and COO to speak at Barclays Global Healthcare Conference on March 13, 2024. Webcast available on Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences
-
Rhea-AI Summary
SOPHiA GENETICS reports strong financial performance in Q4 2023 and FY 2023 with record revenue, customer additions, and cash burn decline. Revenue grew 27% in Q4 and 31% for FY 2023, with improved gross margins and operating loss. Cash burn decreased by 36% year-over-year. The company signed 35 new customers in Q4 2023 and expanded its presence in the U.S. market. SOPHiA DDM™ platform saw significant growth and adoption, with new applications and partnerships driving revenue. The company aims for continued growth in 2024 and profitability in the next 2+ years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
Rhea-AI Summary
SOPHiA GENETICS (SOPH) executives to participate in fireside chat at 44th Annual TD Cowen Health Care Conference. The chat will be webcast live on the company's Investor Relations website, with a replay available post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
conferences
SOPHiA Genetics SA

Nasdaq:SOPH

SOPH Rankings

SOPH Stock Data

326.51M
46.15M
5.92%
49.96%
0.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Switzerland
Rolle

About SOPH

sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and swiss precision. sophia genetics offers health professionals who perform clinical genetic testing unparalleled bioinformatics analysis, quality assurance and secure banking of patient dna sequence data generated by ngs. the company helps clinical laboratories to reduce costs, overcome complexity, significantly improve the turnaround time for routine diagnosis and meet quality requirements related to the use of ngs in the clinic. our solution, the sophia ddm™ platform allows hospitals to better and faster diagnose patients using cutting edge ngs analytics algorithms and through knowledge sharing within the largest clinical genomics community in the world (+100 hospitals). the name « sophia » means wisdom in greek and it is the definition of our excellence based